Combined chemoendocrine treatment with tegafur and tamoxifen for advanced renal cell carcinoma.
Ten patients with advanced renal cell carcinoma were given combined chemoendocrine treatment with tegafur and tamoxifen. Patients were orally administered 800 mg/body tegafur and 20 mg/body tamoxifen daily. One patient was assessed as CR, three as PR, two as NC and four as PD. One out of two patients with estrogen receptor (ER)-positive tumors and three out of four patients with ER-negative tumors responded favorably to this treatment. Side effects observed during treatment included nausea and vomiting (Grade I in three patients and Grade II in five), leukopenia (Grade II in four patients and Grade III in two), Grade II liver dysfunction in two patients, and slight pigmentation in two patients. This treatment can be considered efficacious for renal cell carcinoma.
Wada
T
T
First Department of Surgery, Kinki University School of Medicine, Osaka, Japan.
Nishiyama
K
K
Maeda
M
M
Hara
S
S
Tanaka
N
N
Yasutomi
M
M
Kurita
T
T
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy*; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy*; D011960:Receptors, Estrogen / Q000032:analysis; D013629:Tamoxifen / Q000008:administration & dosage* / Q000009:adverse effects; D005641:Tegafur / Q000008:administration & dosage* / Q000009:adverse effects
D011960:Receptors, Estrogen; D013629:Tamoxifen; D005641:Tegafur